Aligos Therapeutics (NASDAQ:ALGS) Upgraded at Jefferies Financial Group

Jefferies Financial Group upgraded shares of Aligos Therapeutics (NASDAQ:ALGS) to a strong-buy rating in a research note published on Thursday,Zacks.com reports.

ALGS has been the topic of several other reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Aligos Therapeutics in a research note on Wednesday, January 21st. HC Wainwright restated a “buy” rating and issued a $50.00 target price on shares of Aligos Therapeutics in a research note on Wednesday, March 11th. UBS Group assumed coverage on shares of Aligos Therapeutics in a report on Wednesday, January 7th. They issued a “buy” rating and a $20.00 target price on the stock. Westpark Capital initiated coverage on shares of Aligos Therapeutics in a research note on Thursday. They set a “buy” rating and a $48.00 price target on the stock. Finally, Wall Street Zen cut shares of Aligos Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 7th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $41.50.

Aligos Therapeutics Trading Down 5.4%

Shares of ALGS stock opened at $6.66 on Thursday. The business’s 50 day moving average is $7.30 and its two-hundred day moving average is $8.71. Aligos Therapeutics has a twelve month low of $3.76 and a twelve month high of $13.69. The company has a market capitalization of $41.23 million, a P/E ratio of -0.78 and a beta of 2.67.

Aligos Therapeutics (NASDAQ:ALGS) last released its earnings results on Thursday, March 5th. The company reported ($1.91) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.09) by $0.18. Aligos Therapeutics had a negative return on equity of 28.16% and a negative net margin of 1,106.72%.The business had revenue of $0.17 million for the quarter, compared to analyst estimates of $0.27 million. As a group, equities analysts predict that Aligos Therapeutics will post -10.36 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of ALGS. Woodline Partners LP acquired a new stake in Aligos Therapeutics in the first quarter valued at $2,602,000. Marshall Wace LLP acquired a new position in shares of Aligos Therapeutics during the 4th quarter worth $2,504,000. Sio Capital Management LLC grew its stake in shares of Aligos Therapeutics by 85.9% during the 2nd quarter. Sio Capital Management LLC now owns 335,937 shares of the company’s stock worth $2,422,000 after purchasing an additional 155,217 shares during the period. SummitTX Capital L.P. purchased a new position in shares of Aligos Therapeutics in the 4th quarter valued at about $1,299,000. Finally, Verition Fund Management LLC purchased a new position in shares of Aligos Therapeutics in the 4th quarter valued at about $664,000. Hedge funds and other institutional investors own 60.43% of the company’s stock.

Aligos Therapeutics Company Profile

Aligos Therapeutics, Inc is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics for chronic viral infections. The company leverages proprietary nucleic acid chemistry and small‐molecule discovery platforms to create therapies aimed at reducing viral replication, lowering antigen levels and restoring host immune function. Its pipeline includes both oligonucleotide conjugates and orally administered small molecules designed to address the root causes of persistent infections.

Founded in 2014 and headquartered in South San Francisco, California, Aligos advances its programs through strategic collaborations with academic institutions, research hospitals and industry partners.